148 related articles for article (PubMed ID: 30878385)
1. SGL5213, a novel and potent intestinal SGLT1 inhibitor, suppresses intestinal glucose absorption and enhances plasma GLP-1 and GLP-2 secretion in rats.
Io F; Gunji E; Koretsune H; Kato K; Sugisaki-Kitano M; Okumura-Kitajima L; Kimura K; Uchida S; Yamamoto K
Eur J Pharmacol; 2019 Jun; 853():136-144. PubMed ID: 30878385
[TBL] [Abstract][Full Text] [Related]
2. Intestinal Sodium Glucose Cotransporter 1 Inhibition Enhances Glucagon-Like Peptide-1 Secretion in Normal and Diabetic Rodents.
Oguma T; Nakayama K; Kuriyama C; Matsushita Y; Yoshida K; Hikida K; Obokata N; Tsuda-Tsukimoto M; Saito A; Arakawa K; Ueta K; Shiotani M
J Pharmacol Exp Ther; 2015 Sep; 354(3):279-89. PubMed ID: 26105952
[TBL] [Abstract][Full Text] [Related]
3. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose.
Powell DR; Smith M; Greer J; Harris A; Zhao S; DaCosta C; Mseeh F; Shadoan MK; Sands A; Zambrowicz B; Ding ZM
J Pharmacol Exp Ther; 2013 May; 345(2):250-9. PubMed ID: 23487174
[TBL] [Abstract][Full Text] [Related]
4. Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release.
Dobbins RL; Greenway FL; Chen L; Liu Y; Breed SL; Andrews SM; Wald JA; Walker A; Smith CD
Am J Physiol Gastrointest Liver Physiol; 2015 Jun; 308(11):G946-54. PubMed ID: 25767259
[TBL] [Abstract][Full Text] [Related]
5. SGLT-1-specific inhibition ameliorates renal failure and alters the gut microbial community in mice with adenine-induced renal failure.
Ho HJ; Kikuchi K; Oikawa D; Watanabe S; Kanemitsu Y; Saigusa D; Kujirai R; Ikeda-Ohtsubo W; Ichijo M; Akiyama Y; Aoki Y; Mishima E; Ogata Y; Oikawa Y; Matsuhashi T; Toyohara T; Suzuki C; Suzuki T; Mano N; Kagawa Y; Owada Y; Katayama T; Nakayama T; Tomioka Y; Abe T
Physiol Rep; 2021 Dec; 9(24):e15092. PubMed ID: 34921520
[TBL] [Abstract][Full Text] [Related]
6. Protective effect of SGL5213, a potent intestinal sodium-glucose cotransporter 1 inhibitor, in nonalcoholic fatty liver disease in mice.
Honda Y; Ozaki A; Iwaki M; Kobayashi T; Nogami A; Kessoku T; Ogawa Y; Tomeno W; Imajo K; Yoneda M; Saito S; Nagashima Y; Nakajima A
J Pharmacol Sci; 2021 Oct; 147(2):176-183. PubMed ID: 34384565
[TBL] [Abstract][Full Text] [Related]
7. Canagliflozin potentiates GLP-1 secretion and lowers the peak of GIP secretion in rats fed a high-fat high-sucrose diet.
Hira T; Koga T; Sasaki K; Hara H
Biochem Biophys Res Commun; 2017 Oct; 492(2):161-165. PubMed ID: 28803984
[TBL] [Abstract][Full Text] [Related]
8. KGA-2727, a novel selective inhibitor of a high-affinity sodium glucose cotransporter (SGLT1), exhibits antidiabetic efficacy in rodent models.
Shibazaki T; Tomae M; Ishikawa-Takemura Y; Fushimi N; Itoh F; Yamada M; Isaji M
J Pharmacol Exp Ther; 2012 Aug; 342(2):288-96. PubMed ID: 22537769
[TBL] [Abstract][Full Text] [Related]
9. Activation of sodium-glucose cotransporter 1 ameliorates hyperglycemia by mediating incretin secretion in mice.
Moriya R; Shirakura T; Ito J; Mashiko S; Seo T
Am J Physiol Endocrinol Metab; 2009 Dec; 297(6):E1358-65. PubMed ID: 19808907
[TBL] [Abstract][Full Text] [Related]
10. Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects.
Zambrowicz B; Ogbaa I; Frazier K; Banks P; Turnage A; Freiman J; Boehm KA; Ruff D; Powell D; Sands A
Clin Ther; 2013 Aug; 35(8):1162-1173.e8. PubMed ID: 23911260
[TBL] [Abstract][Full Text] [Related]
11. Discovery of potent, low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor SGL5213 for type 2 diabetes treatment.
Kuroda S; Kobashi Y; Oi T; Kawabe K; Shiozawa F; Okumura-Kitajima L; Sugisaki-Kitano M; Io F; Yamamoto K; Kakinuma H
Bioorg Med Chem; 2019 Jan; 27(2):394-409. PubMed ID: 30579799
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and Structure-Activity Relationship of C-Phenyl D-Glucitol (TP0454614) Derivatives as Selective Sodium-Dependent Glucose Cotransporter 1 (SGLT1) Inhibitors.
Kuroda S; Kobashi Y; Kawamura M; Kawabe K; Shiozawa F; Hamada M; Shimizu Y; Okumura-Kitajima L; Koretsune H; Kimura K; Yamamoto K; Kakinuma H
Chem Pharm Bull (Tokyo); 2020; 68(7):635-652. PubMed ID: 32611999
[TBL] [Abstract][Full Text] [Related]
13. Potent Sodium/Glucose Cotransporter SGLT1/2 Dual Inhibition Improves Glycemic Control Without Marked Gastrointestinal Adaptation or Colonic Microbiota Changes in Rodents.
Du F; Hinke SA; Cavanaugh C; Polidori D; Wallace N; Kirchner T; Jennis M; Lang W; Kuo GH; Gaul MD; Lenhard J; Demarest K; Ajami NJ; Liang Y; Hornby PJ
J Pharmacol Exp Ther; 2018 Jun; 365(3):676-687. PubMed ID: 29674332
[TBL] [Abstract][Full Text] [Related]
14. RANTES (CCL5) reduces glucose-dependent secretion of glucagon-like peptides 1 and 2 and impairs glucose-induced insulin secretion in mice.
Pais R; Zietek T; Hauner H; Daniel H; Skurk T
Am J Physiol Gastrointest Liver Physiol; 2014 Aug; 307(3):G330-7. PubMed ID: 24875103
[TBL] [Abstract][Full Text] [Related]
15. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.
Zambrowicz B; Ding ZM; Ogbaa I; Frazier K; Banks P; Turnage A; Freiman J; Smith M; Ruff D; Sands A; Powell D
Clin Ther; 2013 Mar; 35(3):273-285.e7. PubMed ID: 23433601
[TBL] [Abstract][Full Text] [Related]
16. Effect of glucagon-like peptide-2 (GLP-2) on diurnal SGLT1 expression.
Ramsanahie AP; Berger UV; Zinner MJ; Whang EE; Rhoads DB; Ashley SW
Dig Dis Sci; 2004; 49(11-12):1731-7. PubMed ID: 15628694
[TBL] [Abstract][Full Text] [Related]
17. Sweet taste receptor expression in ruminant intestine and its activation by artificial sweeteners to regulate glucose absorption.
Moran AW; Al-Rammahi M; Zhang C; Bravo D; Calsamiglia S; Shirazi-Beechey SP
J Dairy Sci; 2014; 97(8):4955-72. PubMed ID: 24881785
[TBL] [Abstract][Full Text] [Related]
18. TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity.
Yamamoto K; Uchida S; Kitano K; Fukuhara N; Okumura-Kitajima L; Gunji E; Kozakai A; Tomoike H; Kojima N; Asami J; Toyoda H; Arai M; Takahashi T; Takahashi K
Br J Pharmacol; 2011 Sep; 164(1):181-91. PubMed ID: 21410690
[TBL] [Abstract][Full Text] [Related]
19. Changes in glucose-induced plasma active glucagon-like peptide-1 levels by co-administration of sodium-glucose cotransporter inhibitors with dipeptidyl peptidase-4 inhibitors in rodents.
Oguma T; Kuriyama C; Nakayama K; Matsushita Y; Hikida K; Tsuda-Tsukimoto M; Saito A; Arakawa K; Ueta K; Minami M; Shiotani M
J Pharmacol Sci; 2016 Dec; 132(4):255-261. PubMed ID: 27889414
[TBL] [Abstract][Full Text] [Related]
20. Improved glycemic control in mice lacking Sglt1 and Sglt2.
Powell DR; DaCosta CM; Gay J; Ding ZM; Smith M; Greer J; Doree D; Jeter-Jones S; Mseeh F; Rodriguez LA; Harris A; Buhring L; Platt KA; Vogel P; Brommage R; Shadoan MK; Sands AT; Zambrowicz B
Am J Physiol Endocrinol Metab; 2013 Jan; 304(2):E117-30. PubMed ID: 23149623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
